Zenocutuzumab PK and tumor-growth dynamics
A translational PK/PD model coupling zenocutuzumab distribution and nonlinear clearance to concentration-dependent tumor-cell death and net tumor-volume dynamics.
- Therapeutic
- Zenocutuzumab
- Target
- ERBB3, HER3, HER2 / ERBB2
- Disease
- HER2/HER3-driven preclinical tumors and first-in-human translation
Biological model
A translational PK/PD model coupling zenocutuzumab distribution and nonlinear clearance to concentration-dependent tumor-cell death and net tumor-volume dynamics.
Intervention
Zenocutuzumab
Biological focus
ERBB3, HER3, HER2 / ERBB2
Context
HER2/HER3-driven preclinical tumors and first-in-human translation
Model details
A translational PK/PD model coupling zenocutuzumab distribution and nonlinear clearance to concentration-dependent tumor-cell death and net tumor-volume dynamics.
Modeled states
- AUC mg h Lmg*h/L
Modeled dynamic state for auc mg h l.
- central mgmg
Modeled dynamic state for central mg.
- elapsed hh
Modeled dynamic state for elapsed h.
- growth effectdimensionless
Modeled dynamic state for growth effect.
- peripheral mgmg
Modeled dynamic state for peripheral mg.
- tumor mm3millimeter**3
Modeled dynamic state for tumor mm3.
Key readouts
- Central zenocutuzumab concentrationunknown
Model-derived readout for central zenocutuzumab concentration.
- Peripheral zenocutuzumab concentrationunknown
Model-derived readout for peripheral zenocutuzumab concentration.
- Tumor volumemillimeter**3
Model-derived readout for tumor volume.
- Drug-modified tumor growthdimensionless
Model-derived readout for drug-modified tumor growth.
- Cumulative exposuremg*h/L
Model-derived readout for cumulative exposure.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
Human 360 mg every 3 weeks receptor occupancy
How does zenocutuzumab exposure translate into tumor-growth inhibition over time? Explore this intervention regimen through Central zenocutuzumab concentration, Peripheral zenocutuzumab concentration, Tumor volume, Drug-modified tumor growth, Cumulative exposure. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How does zenocutuzumab exposure translate into tumor-growth inhibition over time?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How does zenocutuzumab exposure translate into tumor-growth inhibition over time?
CL L h
Model parameter controlling cl l h.
Exploratory range around the default value.
5 evenly spaced values in L/h. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and doseInvestigational New Drugs
